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Background: Ebola virus disease (EVD) survivors are at risk for uveitis during convalescence. Vision loss has been
observed following uveitis due to cataracts. Since Ebola virus (EBOV) may persist in the ocular ﬂuid of EVD sur-
vivors for an unknown duration, there are questions about the safety and feasibility of vision restorative cataract
surgery in EVD survivors.
Methods:We conducted a cross-sectional study of EVD survivors anticipating cataract surgery and patients with
active uveitis to evaluate EBOV RNA persistence in ocular ﬂuid, as well as vision outcomes post cataract surgery.
Patients with aqueous humor that tested negative for EBOV RNA were eligible to proceed with manual small in-
cision cataract surgery (MSICS).
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Findings:We screened 137 EVD survivors from June 2016 – August 2017 for enrolment.We enrolled 50 EVD sur-
vivors; 46with visually signiﬁcant cataract, 1with a subluxated lens, 2with active uveitis and 1with a blind pain-
ful eye due touveitis. Themedian agewas 24.0 years (IQR 17–35) and 35patients (70%)were female. Themedian
logMAR visual acuity (VA) was 3.0 (Snellen VA Hand motions; Interquartile Range, IQR: 1.2-3.0, Snellen VA 20/
320 – Hand motions). All patients tested negative for EBOV RNA by RT-PCR in aqueous humor/vitreous ﬂuid
and conjunctiva at a median of 19 months (IQR 18-20) from EVD diagnosis in Phase 1 of ocular ﬂuid sampling
and 34 months (IQR 32-36) from EVD diagnosis in Phase 2 of ocular ﬂuid sampling. Thirty-four patients
underwent MSICS, with a preoperative median VA improvement from hand motions to 20/30 at three-month
postoperative follow-up (P b 0.001).
Interpretation: EBOV persistence by RT-PCR was not identiﬁed in ocular ﬂuid or conjunctivae of ﬁfty EVD survi-
vors with ocular disease. Cataract surgery can be performed safely with vision restorative outcomes in patients
who test negative for EBOV RNA in ocular ﬂuid specimens. These ﬁndings impact the thousands of West
African EVD survivors at-risk for ocular complications who may also require eye surgery during EVD
convalescence.
©2018 TheAuthors. Publishedby Elsevier B.V. This is an open access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Uveitis syndromes due to ocular viral infection can lead to signiﬁcant
visual morbidity and blindness (Connors et al., 2015). In addition to
commonly recognized pathogens (e.g. herpes simplex virus, cytomega-
lovirus), emerging viruses (e.g. chikungunya, zika) are increasingly im-
plicated as causes of uveitis (Connors et al., 2015). The West African
Ebola virus disease (EVD) outbreak in 2013–2016 brought attention to
a range of uveitis ﬁndings ranging from anterior uveitis to sight-
threatening panuveitis as a sequelae of Ebola virus infection diagnosed
in 13% to 34% of EVD survivors (Varkey et al., 2015; Tiffany et al.,
2016; Shantha et al., 2017; Hereth-Hebert et al., 2017). A complex dis-
ease spectrumwas noted, leading to severe vision impairment or blind-
ness in nearly 40% of affected eyes (Shantha et al., 2017). Vision loss due
to uveitis impacts overall quality-of-life amidst a number of other clini-
cal sequelae of EVD, including arthralgias, myalgias, headache, and ab-
dominal pain (Epstein et al., 2015; Vetter et al., 2016).
Ebola virus (EBOV) has been noted to persist in immune privileged
sites including the aqueous humor (Varkey et al., 2015) and cerebrospi-
nal ﬂuid (Jacobs et al., 2016), leading to severe uveitis and meningoen-
cephalitis, respectively, during EVD convalescence. Long-term EBOV
RNA detection in semen (Deen et al., 2017; Soka et al., 2016), breast
milk (Sissoko et al., 2017), and placenta (Bower et al., 2016), with
rare transmission events reported (Sissoko et al., 2017; Bower
et al., 2016; Mate et al., 2015; Diallo et al., 2016), highlight the indi-
vidual and public health consequences of EBOV persistence and em-
phasize the urgent need to investigate EBOV RNA clearance from
immune-privileged sites.
In EVD survivors, invasive ophthalmic procedures (e.g. cataract sur-
gery, open globe repair, retinal detachment surgery) currently pose an
uncertain risk of EBOV transmission via ocular ﬂuid to health care
workers and close contacts of EVD survivors. We conducted The Ebola
Virus Persistence in Ocular Tissues and Fluids (EVICT) study to establish
an evidence base for a safe, effective approach to invasive ophthalmic
procedures in EVD survivors. Anterior chamber paracentesis was per-
formed in patients with active uveitis or in patients who require oph-
thalmic surgery to test for EBOV viral persistence before intraocular
surgery. Herein, we report the clinical ophthalmic phenotypes, preva-
lence of EBOV RT-PCR in ocular ﬂuid of a cohort of Sierra Leonean EVD
survivors anticipating ocular surgery or with active uveitis. We also de-
scribe the vision restorative outcomes of patients meeting criteria for
cataract surgery.
2. Methods
We designed a cross-sectional study to evaluate EBOV RNA persis-
tence in ocular ﬂuids and tissues of EVD survivors. Institutional Review
Board approval was obtained from Emory University and the Ofﬁce of
Ethics and Scientiﬁc Review Committee, Sierra LeoneMinistry of Health
and Sanitation (MOHS). Human research was conducted according to
the Tenets of the Declaration of Helsinki, and informed consent was ob-
tained with the assistance of Sierra Leonean interpreters in the native
dialect of enrolled patients. During the ocular ﬂuid sampling portion
of the EVICT Study, patients underwent ocular ﬂuid testing for EBOV
RNA by RT-PCR. Patients who tested negative for EBOV RNA were then
eligible for the surgical portion of the EVICT Study,which includedman-
ual small-incision cataract surgery (MSICS) with intraocular lens (IOL)
implantation when medically indicated.
2.1. EVICT Facility, Study Site Preparation, and Personal Protective
Equipment
Patient ophthalmologic evaluations were conducted at the Lowell
and Ruth Gess Eye Hospital in Freetown, Sierra Leone. An ophthalmic
procedure room was designed adhering to World Health Organization
(WHO) guidelines (World Health Organisation, 2016), and guidance
from the Emory University Serious Communicable Disease Unit
(SCDU), with high-level safety precautions for potential EBOV exposure
(Fig. 1). Eye care providers performed the ocular ﬂuid sampling proce-
dure in full personal protective equipment (PPE) with monitoring
from an infectious disease physician trained in the care of EVD in the
acute Ebola treatment unit (ETU) setting.
2.2. Patient Recruitment
EVD survivors anticipating ophthalmic surgery (cataract and/or ret-
inal surgery) were identiﬁed via an ophthalmic screening program con-
ducted by the MOHS National Eye Care Program from March 2015
through March 2016. In addition, EVD survivors were referred from
local eye clinics for vision loss and cataract evaluation. These centers in-
cluded Connaught Government Hospital (Freetown), Lunsar Baptist Eye
Hospital (Port Loko) and Kenema Government Hospital (Kenema), as
well as direct referral from the Sierra Leone Association of Ebola Survi-
vors (SLAES).
2.3. Patient Screening, Ophthalmic Exam, and Follow-Up
Ophthalmic exams for EVD survivors included corrected visual acu-
ity (VA), pupillary examination, confrontational visual ﬁelds, ocularmo-
tility and intraocular pressure (tonopen, Avia, Reichert Technologies).
Anterior chamber (AC) cell grade was measured per Standardization
of Uveitis Nomenclature guidelines via slit lamp examination (Jabs
et al., 2005). Cataract was classiﬁed as nuclear sclerotic, posterior sub-
capsular, anterior subcapsular, uveitic white cataract, uveitic white cat-
aract with anterior capsular ﬁbrosis, and graded from one to four.
Funduscopic evaluation was performed with a 90- and 28-diopter
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lens. When media opacity (e.g. dense cataract) precluded adequate
view of the retina, a B-scan ultrasound was performed. Patients who
were anticipating intraocular surgery orwith active uveitiswere offered
EVICT enrollment for ocular ﬂuid sampling. Exclusion criteria included
clinical ﬁndings suggesting minimal to no beneﬁt from intraocular
surgery (e.g. chronic tractional retinal detachment by B-scanwould pre-
clude cataract surgery) and was determined by the clinical investigator.
Following their ocular ﬂuid (aqueous humor or vitreous) sampling pro-
cedure, patients were seen at one-day, one-week, and one-month post
procedure. Patients were evaluated sooner when clinically indicated.
Patients who underwent MSICS with IOL implantation were evaluated
at postoperative day one (POD1), at week one (POW1), at month one
(POM1), and at three to four months (POM 3/4).
2.4. Laboratory Workup and Serologic Testing for Causes of Uveitis
Serologic evidence of prior EBOV infection was evaluated on sera
collected from enrolled patients using ReEBOV® IgG ELISA Test Kits
(Zalgen Labs, Germantown,MD) as described in the Supplementary Ap-
pendix by the Kenema Government Hospital Lassa Hemorrhagic Fever
Laboratory. Patients also underwent laboratory evaluation for other
causes of uveitis, including serum testing for HIV 1/2- Antigen-
Antibody (Alere Determine™, San Diego, CA), and syphilis testing by
rapid plasma reagin (RPR). Speciﬁc syphilis antibody testing with FTA-
ABS or syphilis IgG was not available. Serology for Lassa fever (LASV)
IgG using ReLASV™ Pan-Lassa IgG/IgM ELISA Test Kit (Zalgen Labs)
was also performed.
Fig. 1. Schematic blueprint of EVICT facility. Features of the EVICT room for ophthalmic procedures include a unidirectional patient ﬂow with separate entry and exit areas, health care
worker monitoring during donning and dofﬁng of personal protective equipment, and specimen handling protocols for harvesting and storage of specimens in a temperature-
monitored 4 °C refrigerator prior to transportation to reference laboratory.
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2.5. Ocular Fluid Sampling Procedure
We performed ocular ﬂuid sampling in full PPE in a facility with in-
fection prevention measures following guidelines from the WHO and
Emory SCDU (Fig. 1). Patients underwent extra- and intraocular ﬂuid
sampling by Retina Fellowship-trained ophthalmologists. Anterior
chamber paracentesis or vitreous tap was performed as detailed in the
Supplemental Appendix. Approximately 100–200 μl were aspirated
from the aqueous humor and 500 μl were obtained from the vitreous
humor. We obtained conjunctival swabs from the inferior conjunctival
fornix pre-procedure and immediately post procedure with a Dacron
swab, and placed them in viral transport media (Hardy Diagnostics,
Springboro, OH). Ocular ﬂuid sampling proceeded in two phases with
Phase 1 occurring in June 2016 and Phase 2 occurring in July and August
2017. The patients in Phase 1 were largely from Freetown and included
Port Loko and Western Area Districts, whereas the patients in Phase 2
included individuals frommore distant locations including Bo, Kenema,
Moyamba, Tonkolili.
2.6. EBOV Reverse Transcription Polymerase Chain Reaction (RT-PCR) Test-
ing of Ocular Fluid
EBOV RT-PCR was performed on conjunctival swab specimens and
ocular ﬂuid following RNA extraction using the QIAamp Viral RNA
Mini kit (Qiagen, Germantown,MD) at the KenemaGovernment Hospi-
tal (KGH). Patient samples then underwent EBOV RT-qPCR analysis
using the KGH primer set (Gire et al., 2014) and Power SYBR Green
RNA-to-Ct 1-Step qRT-PCR assay (Life Technologies, Carlsbad, CA). The
details of the EBOV RT-PCR procedure are outlined in the Supplemental
Appendix.
2.7. Manual Small-Incision Cataract Surgery Procedure
Patients with ocular ﬂuid specimens that tested negative for EBOV
RNAby RT-PCR had the opportunity to undergoMSICSwith IOL implan-
tation to achieve a postoperative refractive error between−0.50 and
−1.00 diopters. PPE wasmodiﬁed to sterile surgical attire (ﬂuid imper-
vious gown, gloves, mask and shoe covers). The details of MSICS are
summarized in the Supplemental Appendix.
2.8. Statistical Analysis
Data were presented as percentage frequencies as appropriate or
medians with interquartile range (IQR) for continuous variables. VA
was converted to logarithm of the minimal angle of resolution
(logMAR) for statistical analysis. Counting ﬁngers and hand motions
were converted to logMAR as previously described (Holladay, 2004).
Patientswith only light perception or no light perceptionwere excluded
from statistical analyses. We used a paired t-test to compare preopera-
tive to postoperative VA at follow-up. The Jeffrey's interval approach
was used to calculate a conﬁdence interval estimating the true propor-
tion of ocular specimens with EBOV presence. Descriptive and univari-
ate analyses were carried out using Microsoft Excel (v2013, Redmond,
WA) and SAS (v9.3, Cary, NC). All statistical tests were two-sided and
a p value b 0.05 was considered statistically signiﬁcant for all
comparisons.
3. Results
3.1. Characteristics of Screened and Enrolled Patients
We examined 137 EVD survivors from Sierra Leone in from June
2016 – August 2017 (Fig. 2, Consort diagram), of whom 32 (23%)
EVD-survivors showed evidence of cataract but did not fulﬁll EVICT eli-
gibility criteria due to non-visually signiﬁcant (i.e. immature) cataract
(16 patients), retinal or optic nerve disease precluding VA improvement
(11 patients) and hypotony/phthisis bulbi (5 patients). Fifty-one pa-
tients met eligibility criteria and one patient deferred enrollment. Fifty
(35%) EVD survivors were enrolled into the EVICT study for ocular
ﬂuid sampling.
3.2. Baseline Enrolled Patient Characteristics
The median age of the 50 EVD survivor participants was 24.0 years
(IQR 17-35). Thirty-ﬁve patients (70%) were female. The median time
spent in an ETUwas 21 days (IQR14-45). Themedian time fromEVDdi-
agnosis to AC paracentesis in Phase 1 of ocular ﬂuid sampling was
19 months (IQR 18-20); in Phase 2 of ocular ﬂuid sampling, the median
time from EVD diagnosis to AC paracentesis was 34 months (IQR 32-
36 months). The most commonly observed ophthalmic complaints at
the time of EVICT enrollment included vision loss (49%), eye pain
(37%), and tearing (27%) (Supplemental Table 1). Systemic complaints
at study enrollment are summarized in Supplemental Table 2, with
headache, joint pain, and weight loss being most frequently observed.
Themedian logMAR visual acuity of the affected eyeswas 3 (IQR 1.2 –
3.0; Snellen visual acuity equivalent hand motions; IQR 20/320 – Hand
Motions). Thirty eyes (60%) involved the left eye. Indications for enrol-
ment included visually signiﬁcant cataract (46 eyes, 92%), active uveitis
(2 eyes, 4%), subluxed lens (1 eyes, 2%), and blind painful eye due to
chronic uveitis (1 patient, 2%). Cataracts were identiﬁed in 46 (92%) pa-
tients. Uveitic white cataract (25, 54.3%) and posterior subcapsular cat-
aract alone (8, 17.4%) were most frequently seen. Other cataract
subtypes included uveitic white cataract with anterior capsular ﬁbrosis
(4, 8.7%) combination nuclear sclerotic/posterior subcapsular (4, 8.7%),
combination anterior subcapsular/posterior subcapsular (3, 6.5%), and
age-related nuclear sclerotic (2, 4.3%) (Fig. 3).
Two enrollees (4%) had active uveitis, one of whom also had a
non-visually signiﬁcant cataract. Forty-six survivors (92%) had a his-
tory of uveitis. Structural complications in affected eyes included
posterior synechiae (40, 80%), chorioretinal scars (7, 14%), inactive,
pigmented keratic precipitates (9, 18%), active keratic precipitates
(2, 4%) and band keratopathy (3, 6%). B-scan ultrasound was re-
quired due to inadequate view of the posterior segment in 36
(72%) patients (Fig. 4). Ocular treatments prior to study enrollment
included oral prednisone (4, 8%), sulfamethoxazole/ trimethoprim
800mg/160mg and oral prednisone (1, 2%), topical prednisolone ac-
etate 1% (2, 4%) and a combination of topical prednisolone acetate 1%
and oral prednisone (15, 30%).
3.3. Procedures, Safety Monitoring, and Follow-Up
Forty-nine (98%) patients underwent an AC paracentesis and 1 pa-
tient had a vitreous tap. The median volume of the AC paracentesis
was 140 (IQR: 110–170) microliters. The vitreous sample was 500 μl.
We obtained pre-procedure and immediate post procedure conjuncti-
val swabs in all patients. One adverse event was observed following oc-
ular ﬂuid sampling. Speciﬁcally, the patient who underwent the
vitreous tap developed a 1.0 mm hyphema with a transient elevation
of intraocular pressure that resolved to a normal intraocular pressure
with topical prednisolone acetate, atropine, and ocular hypotensives.
Onemonth after the procedure, all patientswere stablewith nonew ad-
verse events. Visual acuities and intraocular pressures remained stable
at 2-months follow-up.
3.4. Laboratory Investigations
Sera collected from enrolled EVD survivors yielded seropositive re-
sults for EBOV IgG in 49 (98%) patients. LASV IgG, HIV, and RPR were
positive in 8 (16%), 1 (2%), and 1 (2%) patients respectively.
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3.5. Ocular Fluid Analysis
Forty-nine aqueous humor samples and one vitreous aspirate
tested EBOV RNA-negative by RT-PCR. Pre-procedure and immediate
post procedure conjunctival swab specimens tested negative by
EBOV RT-PCR in all patients. Following negative testing results for
EBOV RNA of ocular ﬂuid specimens, the 46 patients with visually
signiﬁcant cataract were deemed eligible for MSICS. With all 50 ocu-
lar ﬂuid specimens testing negative for EBOV RNA by RT-PCR, it is es-
timated with 95% conﬁdence that the true EBOV presence in ocular
ﬂuid specimenswould be no greater than 5% in our cohort of patients
assessed.
3.6. Manual Small Incision Cataract Surgery Outcomes
Thirty-four of 46 (74%) patients with visually signiﬁcant cataract
underwentMSICSwith IOL implantation (Fig. 2). Twenty of the patients
(59%) were female. Eighteen patients (53%) had a cataract in the right
eye and thirty patients (88%) required B-scan ultrasound for evaluation
of the posterior segment. Preoperative median logMAR VA (IQR;
Median Snellen VA) improved from 3 (Snellen VA equivalent Hand
motions; IQR 1.0-3.0; IQR 20/200 – Hand motions) to 0.54 (IQR 0.18-
0.78; Median Snellen VA 20/70, IQR 20/30 – 20/120) at POM1 (p b
0.001) and 0.18 (IQR 0-0.69; Median Snellen VA 20/30, IQR 20/20–20/
100) at POM3/4 (Fig. 5).
Fig. 2. CONSORTDiagram depicting Ebola virus disease survivors screened, excluded, and enrolled for EVICT Study. Following negative Ebola virus RT-PCR testing of ocular ﬂuid, survivors
with visually signiﬁcant cataract underwent surgery.
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Twenty-four of 34 eyes (70%) in this cohort met the International
Classiﬁcation of Disease-10 (ICD-10) deﬁnition of blindness in the af-
fected eye with a preoperative VA b 20/400. Of these 24 patients with
poorer than 20/400 visual acuity, 20 patients (83%) improved by 3 or
more lines of visual acuity during follow-up. Of the 34 patients undergo-
ing MSICS, 27 patients experienced VA improvement of ≥3 Snellen eye
chart lines by their ﬁnal visit with 20 patients (60%) demonstrating
VA of 20/40 or better at their last visit. Five patients remained poorer
than 2′/200E (i.e. counting ﬁngers vision) due to vitreoretinal pathol-
ogy. Nine patients underwent yttrium aluminum garnet (YAG)
capsulotomy during follow-up. Monitoring for uveitis recurrences is
ongoing.
4. Discussion
This study is the ﬁrst to systematically evaluate EBOV persistence in
the eyes of EVD survivors with cataract or active inﬂammation. Because
uveitis has been estimated in 13 to 34% of EVD survivors, and cataract
blindness is a disabling, but potentially treatable complication of uveitis,
the study ﬁndings provide initial evidence to directly impact clinical
care and timingof vision rehabilitation via cataract surgery. Amidst pub-
lic health uncertainty around the persistence of EBOV in immune
privileged sites (Varkey et al., 2015), interim WHO guidance includes
the avoidance of elective surgery (i.e. cataract surgery) until further
data is obtained (World Health Organization, n.d.). The step-wise ap-
proach involving ocular screening, ocular ﬂuid sampling, and subse-
quent cataract surgery was safe, feasible, and vision restorative in this
cohort of EVD survivors.
Among the 50 EVD survivors we enrolled, the majority presented
with severe vision impairment or blindness in the affected eye. All 50
tested negative for EBOV RNA by RT-PCR in their ocular ﬂuid and con-
junctiva at a median of 19 months after EVD diagnosis in Phase I of oc-
ularﬂuid sampling and at amedian of 34months after EVD in Phase 2 of
ocular ﬂuid sampling. Survivors with a cataract could then proceedwith
eye surgery with preliminary reassurance to eye care providers that
aqueous humor was free of EBOV by RT-PCR. The 34 EVD survivors
who underwent cataract surgery experienced signiﬁcant VA improve-
ment over three to four months of follow-up. It is particularly notable
that the preoperative vision of over 70% of eyeswas poorer than Snellen
visual acuity 20/400 or big “E” optotype. The vision loss was reversible
with treatment despite signs of previous inﬂammation and the need
for a complex MSICS procedure.
Fig. 3. Slit lamp photographs of cataract in Ebola virus disease (EVD) survivors. Slit lamp photograph of an EVD survivor (A) shows a mature white cataract with posterior synechiae
(yellow arrows) indicating prior uveitis. Slit lamp photograph of an EVD survivor with a 4+ brunescent, age-related nuclear sclerotic cataract (B). A slit lamp photograph of an EVD
survivor shows a distinct combination of anterior and posterior lenticular changes with anterior (light green arrow) and posterior subcapsular cataract (red arrows, C) with highly
refractile cortical deposits at higher magniﬁcation (D).
Fig. 4. B-scan ultrasound of an Ebola virus disease (EVD) survivor with a traction retinal
detachment. A B-scan ultrasound of an EVD survivor with a gain of 70 dB shows
vitreous traction with concomitant retinal detachment and subretinal ﬂuid involving the
macula, which is conﬁrmed by the high-frequency spike on the A-scan (yellow asterisk).
There is subtle globe distortion indicative of early phthisis bulbi (cosmetic deformity of
globe due to chronic low intraocular pressure). EVICT protocol enrolment and surgery
were deferred owing to poor visual prognosis.
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The mechanism by which the dense cataracts leading to blindness
rapidly developed in association with uveitis in EVD survivors is un-
known. Contributing factors may include chronic, untreated inﬂamma-
tion, acute severe episodic inﬂammation, corticosteroid-related factors,
or EBOV persistence. While EBOV persistence in seminal ﬂuid has been
evaluated in several studies (Deen et al., 2017;Mate et al., 2015; Christie
et al., 2015), the clearance dynamics of EBOV from other immune
privileged sites (i.e. eye, central nervous system) require further inves-
tigation. Recent studies in non-human primates have demonstrated
that EBOVmay persist inmonocytes andmacrophages within the vitre-
ous humor in association with uveitis (Zeng et al., 2017). Moreover,
in vitro studies have shown that human retinal pigment epithelial
cells are permissive to EBOV infection (Smith et al., 2017).
Limitations of this cross-sectional study include the length of time
after acute EVD when ocular ﬂuid sampling occurred. Speciﬁcally, our
study cannot determine if survivors with uveitis may have harbored
EBOV in their eye at earlier time points when ocular inﬂammation
was active. Although the RT-qPCR is very sensitive, the low amount of
sample extracted could affect the ability to capture EBOV RNA, espe-
cially when using conjunctival swabs, which have very little total RNA.
Moreover, only approximately 50–150 μl of aqueous humor can be
safely obtained from the anterior chamber of the eye to avoid complica-
tions, which include ocular hypotony, hyphema, damage to the lens
capsule, and vision loss. Nonetheless, it currently remains unknown
whether EBOV may persist at low levels after infection, which remain
beneath the threshold of detection of RT-PCR, or in other locations
within the eye, which were not speciﬁcally assessed in this study. An-
other limitation in the evaluation of cataract outcomes was the variable
follow-up. The majority of patients, however, returned for their 3-
month follow-up appointments and their visual acuity outcomes
showed statistically signiﬁcant and clinically meaningful improvement.
Future study considerations include assessment of survivors at time
points earlier than 19 months, patients with active uveitis, and a larger
sample size. While our study ﬁndings in 50 EVD survivors support that
the expected true proportion of EBOV RNA-positive patients would be
no greater than 5% in a comparable patient population, a larger sample
size could provide greater reassurance to eye care providers performing
invasive surgical procedures to restore vision. Speciﬁcally, theminimum
number of subjects testing negative for EBOV RNA by RT-PCR to achieve
a 95% conﬁdence interval of 0.99–1.00 (i.e. expected proportion of EBOV
RNA positive samples ≤1%) is 250.
In summary, the EVICT Study provides the ﬁrst systematically col-
lected evidence evaluating EBOV persistence in ocular ﬂuid of EVD sur-
vivors. We also demonstrate that cataract surgery can be performed
safely with vision restorative outcomes. Given the magnitude of the
West African EVD outbreak and the thousands of survivors at risk of
complications of uveitis, including cataract, efforts to address the ongo-
ing ophthalmic medical and surgical needs of survivors are urgently
needed.
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